Oravax’s virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India NEW YORK, July 21, 2021 – Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development… Read More »Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
Washington/Dubai: Imagine a COVID-19 vaccine that came as a pill: no needles, no medical professionals required to administer it, potentially delivered directly to people’s homes. Israeli pharmaceutical Oramed is attempting to accomplish just that, and is poised to start its first clinical trial in early August, CEO Nadav… Read More »An oral COVID vaccine is nearly ready, will it help end the pandemic?
TOPLINE Amid rising cases of Covid-19 driven by the infectious Delta variant, Israel is gearing up to host the first clinical trials of an oral Covid-19 vaccine, which could help boost access to vaccines around the world and serve as a more convenient booster in the future. KEY… Read More »Oral Covid Vaccine Set To Begin Trials In Israel
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single oral dose administration… Read More »Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines